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2011 will mark the 30
th anniversary of the first descrip-
tion of AIDS, and the 15
th year since combination anti-
retroviral therapy (ART) was introduced. Since its
introduction, ART has had profound impact on AIDS
incidence and mortality in industrialized countries, and
international collaboration, mainly through the Global
Fund and the President’s Emergency Plan for AIDS
Relief, has provided treatment to more than 4 million
HIV-infected persons in low and middle income
settings.
Despite these advances and much speculation, the full
prevention benefits of ART still await clarification.
Experience with mother-to-child transmission of HIV
gave insight into the critical importance of HIV RNA as
the dominant risk factor for HIV transmission, as well
as proof of concept that ART reduced transmission
rates through lowering viral load. Important studies
published in 2010 include evidence that among couples
discordantly infected with HIV, a 92% reduction in
transmission occurred when the infected index was tak-
ing ART (Donnell D, et al. Lancet 2010). The concept
has arisen of community viral load as a risk factor for
community-wide transmission (Das-Douglas, CROI
2010), and ecologic evidence has been presented of ART
scale-up correlating with reduced HIV incidence at the
population level (Lima VD, Lancet 2010). These obser-
vations suggest more widespread ART among HIV-
infected persons (“test and treat”) could provide sub-
stantial prevention benefit but data on such an approach
are awaited, despite several mathematical models exam-
ining this.
ART may provide prevention benefit when given as
post-exposure prophylaxis and possibly as pre-exposure
prophylaxis. The recent widely acclaimed study of a
tenofovir-containing gel, associated with 39% protective
efficacy against HIV acquisition in women on primary
analysis (Karim QA, Science 2010), provides evidence of
efficacy of pre-exposure prophylaxis as well as the feasi-
bility of an efficacious microbicide. Results of trials of
oral pre-exposure prophylaxis will become available in
the near future.
These developments occur in a global context of
financial economic downturn, increased attention to the
other health-related millennium development goals, and
an emerging pandemic of non-communicable diseases.
How to use ART most effectively and comprehensively
for HIV prevention will challenge decision makers, even
as evidence for individual approaches mounts.
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